[Drug-induced nephrotic syndrome].
Kuroki
Aki
A
Department of Nephrology, Showa University, School of Medicine.
Akizawa
Tado
T
Koshikawa
Shozo
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000928:Antidepressive Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D003545:Cysteine / Q000009:adverse effects / Q000031:analogs & derivatives; D004164:Diphosphonates / Q000009:adverse effects; D017612:Gold Compounds / Q000009:adverse effects; D006801:Humans; D007372:Interferons / Q000009:adverse effects; D018020:Lithium Compounds / Q000009:adverse effects; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D000077268:Pamidronate; D010396:Penicillamine / Q000009:adverse effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000928:Antidepressive Agents; D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D017612:Gold Compounds; D018020:Lithium Compounds; D007372:Interferons; D010396:Penicillamine; D003545:Cysteine; D000077268:Pamidronate; C026535:bucillamine